Form 4: CURIS CEO Converts Preferred Stock to Common Shares

CURIS Inc.'s President and CEO, James E. Dentzer, converted 100 shares of Series B Convertible Preferred Stock into 133,333 shares of common stock.

Summary

• James E. Dentzer, President & CEO, Director, and 10% Owner of CURIS INC, converted Series B Convertible Preferred Stock into common stock.
• On March 20, 2026, 100 shares of Series B Convertible Non-Redeemable Preferred Stock automatically converted.
• Each preferred share converted into 1,333.33 shares of common stock, resulting in the acquisition of 133,333 common shares.
• No additional consideration was paid for the conversion.
• Following this transaction, Dentzer beneficially owns 148,730 shares of CURIS INC common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting a pre-scheduled conversion of preferred stock into common shares by a key executive, which aligns management's interests with common shareholders.

Positives

• The conversion of preferred stock to common stock by a key executive indicates continued alignment of interests with common shareholders.
• The transaction was pre-arranged under a Rule 10b5-1(c) plan, suggesting a planned long-term strategy rather than an immediate market reaction.

Industry Context

StockSavvy.ai notes that insider conversions of preferred stock to common stock are a routine part of executive compensation and investment structures, often pre-planned to manage tax implications and avoid accusations of trading on material non-public information. This specific conversion reflects the terms of the original preferred stock issuance.

Comparison to Industry Standards

• Conversions of preferred stock by executives are standard practice in the biotech and pharmaceutical industries, where early-stage funding often involves complex equity structures.
• The use of a Rule 10b5-1 plan aligns with best practices for insider trading compliance, similar to executives at companies like Biogen or Vertex Pharmaceuticals who regularly disclose pre-scheduled transactions.

Related Party Transactions

• James E. Dentzer, the reporting person, originally purchased the Series B Preferred Stock along with associated warrants (collectively, a "Security") at a price of $1,000.00 per Security.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's equity holdings with common shareholders.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled conversion of preferred stock to common stock by the CEO. While it increases the CEO's direct common stock holdings, it does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. It primarily reflects the execution of existing equity terms and insider compliance practices.

Keywords

CURIS INC, CRIS, Form 4, Insider Transaction, Stock Conversion, James E. Dentzer, Preferred Stock, Common Stock, CEO, Director, 10b5-1 Plan